Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1633 1638 1671 1672 1674 1675
This examiner grants 67% of resolved cases
Danyal Hassan Alam is an examiner in Tech Center 1600, Art Unit 1600. The examiner has 6 resolved cases. The allowance rate for these cases is 66.7 percent. The median days to allowance is 1174, which is the time required for those cases to be granted. These figures offer a basis for evaluating prosecution strategies in this art unit.
The interview lift for this examiner is 0.0 percent. This figure shows that for the cases resolved, an interview did not change the outcome or was not utilized. The 0.0 percent lift is lower than the 66.7 percent allowance rate. With 6 resolved cases, the data provides a set of outcomes for practitioners to analyze. The 1174 days to allowance serves as a benchmark for the duration of the prosecution process in Art Unit 1600. These figures assist in planning strategies for applications in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18555087 | RESPIRATORY VIRUS COMBINATION VACCINES | Final Rejection | ModernaTX, Inc. |
| 18555130 | INFLUENZA-CORONAVIRUS COMBINATION VACCINES | Final Rejection | ModernaTX, Inc. |
| 17638451 | ADENO-ASSOCIATED VIRUSES AND METHODS AND MATERIALS FOR MAKING AND USING ADENO-ASSOCIATED VIRUSES | Non-Final OA | The Regents of the University of California |
| 17767389 | HIGHLY MULTIPLEXED DETECTION OF NUCLEIC ACIDS | Final Rejection | The Johns Hopkins University |
| 18444305 | COMPOSITIONS AND METHODS OF USE FOR HUMAN RHINOVIRUSES | Non-Final OA | University of Utah Research Foundation |
| 18280329 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | Non-Final OA | Universität Basel |
| 18685041 | IgA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION | Non-Final OA | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY |
| 18022033 | CORONAVIRUS NANOBODIES AND METHODS FOR THEIR USE AND IDENTIFICATION | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18350454 | METHODS AND COMPOSITIONS FOR SENSITIZING PRC2 MUTANT TUMORS TO IMMUNE CHECKPOINT BLOCKADE THERAPY | Final Rejection | Sloan-Kettering Institute for Cancer Research |
| 18706610 | LENTIVIRAL VECTOR FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS | Non-Final OA | INSTITUT PASTEUR |
| 17612410 | Method for Generation of Genetically Modified T Cells | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | Final Rejection | Inovio Pharmaceuticals, Inc. |
| 18341330 | CORONAVIRUSES, VACCINES COMPRISING THE SAME, AND METHODS FOR PREVENTING DISEASE | Non-Final OA | LOYOLA UNIVERSITY OF CHICAGO |
| 17638143 | PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER | Non-Final OA | Bionoxx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy